Loading the companies…
Loading the companies…
Loading the companies…
Companies › Competitive landscape
52 companies on innovation pace, recall and report signals, commercial momentum and financial capacity, each against the others in breast biopsy & localization. The procedure’s market
In 2025, 28 companies spent $11M in consulting, speaking, meals and travel tied to breast biopsy & localization products with the surgeons MedaRep tracks; Exact Sciences spent the most, 37%. Royalties are left out.
In 2025, surgeons Hologic engaged on breast biopsy & localization products did 0% of the family’s Medicare cases, the most of any company. 100% of cases sit with surgeons no company engaged past $500 for these products: where a line you carry meets the least engagement. See who they are in your territory.
| Firm | Cases | Share | Surgeons | Full reach | Reported |
|---|---|---|---|---|---|
| Hologic | 203 | 0% | 5 | 203 | $13k |
| Other firms | 301 | 0% | 4+ | 151+ | $63k |
| No tie over $500 | 125,021 | 100% | 3662 |
125,525 Medicare cases by 3676 surgeons; 0% sit with surgeons at least one firm engaged past $500 in 2025. Your plan names the top 3 firms; paid plans name eight.
Click a year to show it in the donut and table. Years after 2024 reuse that year’s cases, the newest Medicare file.
| Firm · cases | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Hologic | 0 | 0 | 319 | 206 | 46 | 260 | 203 |
| Leica Microsystems | 0 | 0 | 676 | 257 | 222 | 206 | 0 |
| Other firms | 483 | 125 | 325 | 465 | 725 | 900 | 301 |
| No tie over $500 | 136,974 | 113,045 | 133,056 | 129,449 | 128,348 | 124,159 | 125,021 |
A company is counted for a surgeon when its Open Payments to them in a program year total more than $500 (devices and supplies; drug and biological payments left out). The surgeon’s Medicare fee-for-service cases for breast biopsy & localization then count toward the company, a surgeon several companies engage split between them by dollars, so the slices add up to the family’s cases in the states loaded. Switch the ribbon to dollars to read engagement instead of volume. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Cases lag payments, so each payment year is read against the latest Medicare year at or before it.
Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. FDA counts are 510(k), De Novo and PMA decisions under the category’s product codes.